SynthesisFrontiers in immunology2025
A comprehensive bibliometric analysis of ferroptosis in tumor resistance: development and emerging trends.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ferroptosis in intracerebral hemorrhage: a bibliometric overview of mechanisms and future directions.Frontiers in cellular neuroscience · 2026Pooled it
- The research landscape and future of targeting super-enhancers for cancer therapy: a bibliometric analysis.Discover oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ferroptosis is a regulated form of cell death characterized by iron dependency, lipid peroxidation, and oxidative stress. Since its discovery in 2012, ferroptosis has attracted significant interest for its potential to counteract tumor resistance across various therapeutic modalities, including chemotherapy, radiotherapy, immunotherapy, and targeted therapy. Despite notable progress, a systematic understanding of its underlying molecular mechanisms and translational potential remains underdeveloped, thus necessitating a comprehensive bibliometric analysis. Methods: We employed bibliometric tools, including VOSviewer, CiteSpace, and bibliometric.com, to analyze 2,663 articles related to ferroptosis and tumor resistance indexed in the Web of Science Core Collection from 2014 to 2024. The analysis included co-occurrence, co-citation, and clustering techniques to explore trends, influential keywords, prominent journals, leading institutions, and key contributors. Citation burst detection and temporal analysis were used to uncover emerging research hotspots and track the field's evolution. Results: Over the past decade, the volume of publications in this field has grown rapidly, with China and the United States leading in both research output and academic influence. Notable institutions such as Central South University and Fudan University contributed significantly, while Kang Rui and Tang Daolin emerged as prolific authors. Key research hotspots identified include oxidative stress, tumor microenvironment, and nanomedicine, with emerging themes such as immunotherapy and autophagy gaining prominence. Temporal trends indicated a shift from mechanistic studies toward translational applications, emphasizing the integration of ferroptosis in clinical strategies to address tumor resistance. Conclusions: This bibliometric analysis highlights ferroptosis as a rapidly evolving field with significant contributions to understanding tumor resistance mechanisms. The identification of emerging themes and promising research directions offers valuable insights for future investigations and clinical applications of ferroptosis in overcoming tumor resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.